

Carfilzomib or bortezomib in combination with lenalidomide in newly diagnosed multiple myeloma without autologous stem-cell transplantation (ENDURANCE): a randomised, controlled trial

Lancet Oncology, The
21, 1317-1330

DOI: [10.1016/s1470-2045\(20\)30452-6](https://doi.org/10.1016/s1470-2045(20)30452-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Multiple myeloma current treatment algorithms. Blood Cancer Journal, 2020, 10, 94.	6.2	178
2	Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncology, The, 2020, 21, e540.	10.7	6
3	Treatments for newly diagnosed multiple myeloma: when endurance is interrupted – Authors' reply. Lancet Oncology, The, 2020, 21, e541.	10.7	0
4	Recent Advances in the Treatment of Patients with Multiple Myeloma. Cancers, 2020, 12, 3576.	3.7	22
5	A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. Genes, 2020, 11, 1453.	2.4	2
6	Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decades. Nephrology Dialysis Transplantation, 2022, 37, 1616-1626.	0.7	11
7	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as first-line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	4.1	13
8	A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2021, 96, 226-233.	4.1	5
9	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLoS Medicine, 2021, 18, e1003454.	8.4	18
10	Practical management and assessment of primary plasma cell leukemia in the novel agent era. Cancer Treatment and Research Communications, 2021, 28, 100414.	1.7	1
11	Old and new generation immunomodulatory drugs in multiple myeloma. Panminerva Medica, 2021, 62, 207-219.	0.8	4
12	Highly-efficient production of spherical co-agglomerates of drugs<i>via</i> an organic solvent-free process and a mechanism study. Green Chemistry, 2021, 23, 2710-2721.	9.0	22
13	Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye. Leukemia and Lymphoma, 2021, 62, 1544-1553.	1.3	4
14	A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer Journal, 2021, 11, 23.	6.2	31
15	Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma. Global Journal of Cancer Therapy, 2021, , 010-015.	0.1	0
16	Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Advances, 2021, 5, 1092-1096.	5.2	23
17	How to Treat High-Risk Myeloma at Diagnosis and Relapse. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 291-309.	3.8	27
18	The initial management of multiple myeloma in the era of novel agents: 2021 and beyond. British Journal of Haematology, 2021, 193, 213-215.	2.5	0

#	ARTICLE	IF	CITATIONS
19	Immunomodulators in newly diagnosed multiple myeloma: current and future concepts. Expert Review of Hematology, 2021, 14, 365-376.	2.2	4
20	Up-front ixazomib in older patients with myeloma. Blood, 2021, 137, 3584-3586.	1.4	0
21	Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood, 2021, 138, 113-121.	1.4	22
22	Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma. ACS Pharmacology and Translational Science, 2021, 4, 1050-1065.	4.9	11
23	Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma. Drugs, 2021, 81, 825-840.	10.9	6
24	KRd: the new KiD in the French myeloma induction class. Blood, 2021, 138, 105-106.	1.4	0
25	In search of the optimal proteasome inhibitor. How, when and for whom?. Haematologica, 2021, 106, 2539-2541.	3.5	0
26	Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma. Current Hematologic Malignancy Reports, 2021, 16, 148-161.	2.3	4
27	Current approaches to management of high-risk multiple myeloma. American Journal of Hematology, 2021, 96, 854-871.	4.1	19
28	Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer Journal, 2021, 11, 83.	6.2	64
29	Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK <i>five</i>). Haematologica, 2021, 106, 2694-2706.	3.5	6
30	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of Hematology, 2021, 100, 2325-2337.	1.8	21
31	Advances in Management for Older Adults With Hematologic Malignancies. Journal of Clinical Oncology, 2021, 39, 2102-2114.	1.6	24
32	Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 701-710.	0.4	4
33	Sequencing of myeloma therapy: Finding the right path among many standards. Hematological Oncology, 2021, 39, 68-72.	1.7	6
34	Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma. Leukemia and Lymphoma, 2021, 62, 3087-3097.	1.3	5
35	Knowing the unknowns in high risk multiple myeloma. Blood Reviews, 2022, 51, 100887.	5.7	6
36	Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020. Chronic Diseases and Translational Medicine, 2021, 7, 220-226.	1.2	10

#	ARTICLE	IF	CITATIONS
37	Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. <i>British Journal of Haematology</i> , 2022, 196, 105-109.	2.5	30
38	Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4666.	3.7	10
39	Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 1554-1562.	4.1	1
40	Roadmap to cure multiple myeloma. <i>Cancer Treatment Reviews</i> , 2021, 100, 102284.	7.7	44
41	Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100444.	1.7	5
42	Plasma Cell Neoplasms. , 2021, , 361-375.		0
43	New regimens and directions in the management of newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 367-378.	4.1	8
44	Supportive care in multiple myeloma: Current practices and advances. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100476.	1.7	5
45	Current Updates on the Management of AL Amyloidosis. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 147-161.	1.0	9
46	Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients. <i>Expert Review of Hematology</i> , 2021, , 1-14.	2.2	1
47	Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103504.	4.4	4
48	Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11595.	4.1	26
49	A Hypoxia-Associated Prognostic Gene Signature Risk Model and Prognosis Predictors in Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 726794.	2.8	6
50	How I treat frontline transplantation-eligible multiple myeloma. <i>Blood</i> , 2022, 139, 2882-2888.	1.4	9
51	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 83.e1-83.e9.	1.2	9
52	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1705-1720.	10.7	120
53	Current Treatment Approaches to Newly Diagnosed Multiple Myeloma. <i>Oncology Research and Treatment</i> , 2021, 44, 690-699.	1.2	11
54	Pretransplant Determinants of Outcome in Patients with Myeloma Undergoing Autologous Transplantation in Lower Resource Settings. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 101-110.	3.0	0

#	ARTICLE	IF	CITATIONS
55	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. <i>Seminars in Oncology</i> , 2022, 49, 19-26.	2.2	5
56	Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 442-459.	0.4	7
57	Diagnosis and Management of Multiple Myeloma. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 464.	7.4	308
58	Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. <i>Leukemia</i> , 2022, 36, 613-624.	7.2	11
59	Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, 562-573.	4.1	3
60	Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?. <i>Cells</i> , 2022, 11, 606.	4.1	8
61	Persistent opioid use in patients with multiple myeloma post-ASCT. <i>European Journal of Haematology</i> , 2022, , .	2.2	1
62	Symptom clusters and quality of life in ambulatory patients with multiple myeloma. <i>Supportive Care in Cancer</i> , 2022, 30, 4961-4970.	2.2	5
63	Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. <i>Advances in Therapy</i> , 2022, 39, 1976-1992.	2.9	10
64	Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. <i>Blood Cancer Journal</i> , 2022, 12, 47.	6.2	19
65	Current approaches to management of newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	18
66	Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients. <i>Blood Cancer Journal</i> , 2022, 12, 53.	6.2	4
67	Ikars Proteins in Tumor: Current Perspectives and New Developments. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 788440.	3.5	5
68	Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances. <i>Leukemia and Lymphoma</i> , 2022, 63, 1236-1241.	1.3	2
69	High-risk multiple myeloma: how to treat at diagnosis and relapse?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 30-36.	2.5	15
70	Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	12
71	Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. <i>Leukemia and Lymphoma</i> , 2022, 63, 2413-2421.	1.3	1
72	Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 654-674.	1.9	7

#	ARTICLE	IF	CITATIONS
73	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1142-1149.	2.4	7
74	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e403-e414.	4.6	23
75	Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma. <i>Lancet Haematology</i> , 2022, , .	4.6	0
76	Multiple myeloma with high-risk cytogenetics and its treatment approach. <i>International Journal of Hematology</i> , 2022, 115, 762-777.	1.6	30
77	Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2022, 97, 1086-1107.	4.1	208
78	Construction and evaluation of detachable bone-targeting MOF carriers for the delivery of proteasome inhibitors. <i>RSC Advances</i> , 2022, 12, 14707-14715.	3.6	5
79	Moving Toward a Cure for Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 1-12.	3.8	2
80	High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	26
81	Pathogenesis and treatment of multiple myeloma. <i>MedComm</i> , 2022, 3, .	7.2	8
82	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 132-147.	27.0	173
83	The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma. <i>Translational Oncology</i> , 2022, 22, 101448.	3.7	5
84	Triplet RVD Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Advances in Therapy</i> , 2022, 39, 3799-3834.	2.9	1
85	Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e1000-e1008.	0.4	1
86	Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. <i>British Journal of Haematology</i> , 2022, 199, 190-204.	2.5	9
87	Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent. <i>JAMA Oncology</i> , 2022, 8, 1278.	7.1	14
89	Treatment horizon in multiple myeloma. <i>European Journal of Haematology</i> , 2022, 109, 425-440.	2.2	6
90	MULTIPLE MYELOMA: NARRATIVE REVIEW. , 2022, , 102-104.		0
91	Prognostic Stratification of Multiple Myeloma Using Clinicogenomic Models: Validation and Performance Analysis of the IAC-50 Model. <i>HemaSphere</i> , 2022, 6, e760.	2.7	4

#	ARTICLE	IF	CITATIONS
92	Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 568-578.	1.6	32
93	CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 4492.	3.7	12
94	Updates on Multiple Myeloma: What's New in Risk Stratification, Treatment, and Prognosis. , 0, , .		0
95	Roadmap for new practitioners to navigate the multiple myeloma landscape. <i>Heliyon</i> , 2022, 8, e10586.	3.2	0
96	Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30715.	1.0	0
97	An update on the safety of ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 0, , 1-18.	2.4	0
99	Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2023, 64, 407-414.	1.3	0
100	An expanded lexicon for the ubiquitin code. <i>Nature Reviews Molecular Cell Biology</i> , 2023, 24, 273-287.	37.0	91
101	Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103842.	4.4	5
102	Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 6216.	3.7	6
103	Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib+ cyclophosphamide+ dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. <i>Lancet Haematology</i> , 2023, 10, e93-e106.	4.6	8
104	Newly diagnosed multiple myeloma: making sense of the menu. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 539-550.	2.5	1
105	Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival. <i>American Journal of Hematology</i> , 2023, 98, 413-420.	4.1	4
106	Addressing Modern Diagnostic Pathology for Patient-Derived Soft Tissue Sarcosphere Models in the Era of Functional Precision Oncology. <i>Laboratory Investigation</i> , 2023, , 100039.	3.7	3
107	Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone. <i>Anticancer Research</i> , 2023, 43, 157-165.	1.1	1
108	How I treat multiple myeloma in geriatric patients. <i>Blood</i> , 2024, 143, 224-232.	1.4	5
109	Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
110	Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, e213-e221.	0.4	4

#	ARTICLE	IF	CITATIONS
111	Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies. <i>JACC: CardioOncology</i> , 2023, 5, 1-21.	4.0	7
113	Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy. <i>Blood Cancer Journal</i> , 2023, 13, .	6.2	5
114	30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma. <i>Cancers</i> , 2023, 15, 1929.	3.7	4
116	Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH). <i>Clinical Hematology International</i> , 2023, 5, 112-121.	1.7	3
117	Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment. <i>Cancers</i> , 2023, 15, 2418.	3.7	0
119	First-line treatment of multiple myeloma in both transplant and non-transplant candidates. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 685-698.	2.4	0
120	Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. <i>Blood Reviews</i> , 2023, 61, 101100.	5.7	2
121	Encapsulation of Nano-Bortezomib in Apoptotic Stem Cell-Derived Vesicles for the Treatment of Multiple Myeloma. <i>Small</i> , 2023, 19, .	10.0	5
122	Decellularized Extracellular Matrix: The Role of This Complex Biomaterial in Regeneration. <i>ACS Omega</i> , 2023, 8, 22256-22267.	3.5	2
123	Examination of two different proteasome inhibitors in reactivating mutant human cystathionine β -synthase in mice. <i>PLoS ONE</i> , 2023, 18, e0286550.	2.5	1
124	A systematic approach towards missing lab data in electronic health records: A case study in non-small cell lung cancer and multiple myeloma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 1201-1212.	2.5	1
125	A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (<scp>CAMEL</scp>). <i>American Journal of Hematology</i> , 0, , .	4.1	0
126	Cancer treatment-related cardiotoxicity: a focus on sacubitril/valsartan. <i>Cardiology Plus</i> , 0, Publish Ahead of Print, .	0.7	0
128	Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma. <i>Haematologica</i> , 0, , .	3.5	0
129	Aiming for the cure in myeloma: Putting our best foot forward. <i>Blood Reviews</i> , 2023, , 101116.	5.7	2
130	Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. <i>American Journal of Hematology</i> , 0, , .	4.1	0
131	ASH highlights 2022â€™ multiple myeloma. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.5	1
132	Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, , .	0.4	1

#	ARTICLE	IF	CITATIONS
133	Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma. <i>Dermatopathology (Basel)</i> , 2023, 10, 105-109.	1.5	0
134	Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2023, 13, .	6.2	1
135	Multiple Myeloma: Current Clinical Landscape and Compounding Costs. <i>Current Hematologic Malignancy Reports</i> , 2023, 18, 201-215.	2.3	0
137	Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. <i>Haematologica</i> , 0, , .	3.5	0
138	New Biological Therapies for Multiple Myeloma. <i>Annual Review of Medicine</i> , 2024, 75, .	12.2	0
139	Comparison of health care costs and resource utilization for commonly used proteasome inhibitor+immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 0, , 1-14.	0.9	0
140	ĐŸĐµŃŃĐ;ĐµĐ°Ń,Đ,Đ²Ń< Đ;ŃŃĐ,Đ¼ĐµĐ½ĐµĐ½Đ,Ń•Đ,Đ¼Đ¼ŃfĐ½Đ¾Đ¼Đ¾ĐŃfĐ»Đ,ŃŃfŃŃŃ%Đ,Ń... ĐgŃŃĐµĐ;ĐŃŃĐ°Ń,Đ		
141	MRD negativity: considerations for older adults with multiple myeloma. <i>Blood Cancer Journal</i> , 2023, 13, .	6.2	0
142	IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?. <i>Life</i> , 2023, 13, 2229.	2.4	0
143	Multiple Myeloma in 2023 Ways: From Trials to Real Life. <i>Current Oncology</i> , 2023, 30, 9710-9733.	2.2	1
144	Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians. <i>Blood Cancer Journal</i> , 2023, 13, .	6.2	2
145	Lenalidomide use in multiple myeloma (Review). <i>Molecular and Clinical Oncology</i> , 2023, 20, .	1.0	1
146	Autologous Stem Cell Transplant in Hodgkin+™s and Non-Hodgkin+™s Lymphoma, Multiple Myeloma, and AL Amyloidosis. <i>Cells</i> , 2023, 12, 2855.	4.1	0
147	A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory. <i>International Immunopharmacology</i> , 2024, 127, 111446.	3.8	0
148	Management of Newly Diagnosed Multiple Myeloma Today, and in the Future. <i>Hematology/Oncology Clinics of North America</i> , 2024, 38, 441-459.	2.2	0
149	Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 0, , .	0.9	0
150	Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma. <i>Signal Transduction and Targeted Therapy</i> , 2024, 9, .	17.1	0
151	Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. <i>Blood Cancer Journal</i> , 2024, 14, .	6.2	0

#	ARTICLE	IF	CITATIONS
152	Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
153	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0
154	Targeting RAF dimers in RAS mutant tumors: From biology to clinic. <i>Acta Pharmaceutica Sinica B</i> , 2024, , .	12.0	0
155	Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma. <i>Annals of Hematology</i> , 0, , .	1.8	0